Navigation Links
Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014
Date:9/1/2014

DUBLIN, Sept. 1, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the " Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014" report to their offering.

This report is a comprehensive analysis and market study of new developments relating to early-stage minimally-invasive biomarkers in Alzheimer's disease, which have been 'functionally reviewed' alongside existing AD drugs and candidates in the AD drug pipeline, and applicable commercial AD diagnostics.

New advances have been made in the discovery and validation of biomarkers in Alzheimer's disease (AD), offering much-needed opportunities to accelerate disease research, drug discovery and the development of low-cost minimally-invasive tests that will be available to much wider patient populations.

This report gives a comprehensive and up-to-date analysis of new findings relating to the discovery and clinical evaluation of AD-related biomarkers with potential to allow early detection or progression of this disease, based on minimally-invasive or non-invasive methods. With a focus on controlled human studies of AD, these biomarker findings are 'functionally reviewed' alongside drugs and drug candidates in the development pipeline, and a market analysis of applicable (minimally-invasive) AD-related diagnostics tests, platforms and developments. This report also includes an analysis of related opportunities in AD research, drug discovery, clinical trials and clinical diagnostics.

Key Topics Covered:

Executive Summary

Chapter 1. Background

Chapter 2. Blood Biomarkers

Chapter 3. Autoantibodies

Chapter 4. Urinary Biomarkers

Chapter 5. Salivary Biomarkers

Chapter 6. Other Biomarkers

Chapter 7. AD Drug Pipeline

Chapter 8. Diagnostics Companies of Minimally-Invasive AD Diagnostics

Chapter 9. An Integrated Analysis of AD Biomarkers

Chapter 10. Conclusions and Opportunities

For more information visit http://www.researchandmarkets.com/research/mh4stv/_earlystage

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
2. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
3. Varian Medical Systems to Support an NCI-Sponsored Phase III Study Comparing Radiosurgery with Surgery for the Treatment of Early-Stage High-Risk, Operable Non-Small Cell Lung Cancer
4. DioGenix Issued Seminal Patent for Diagnosing Early-stage Neurological Diseases
5. PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry
6. Emerging Drug Delivery Technologies, Profiles of Start-ups and Early-Stage Companies
7. Study Suggests that a Single Session of Stereotactic Body Radiation Therapy (Lung Radiosurgery) is a Promising Approach for Treating Inoperable Early-Stage Lung Cancer
8. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
9. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
10. Studies Published in Pain Medicine Demonstrate Effectiveness of Minimally-Invasive Cooled Radiofrequency Treatment for Low Back Pain
11. Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... -- MJAC2017 , the premier cannabis event devoted to ... its leading lineup. MJAC2017 is proud ... specializing in the development of pharmaceutical and consumer products, will ... The Green Organic Dutchman are gold sponsors for the event, ... ...
(Date:8/15/2017)... , Aug. 15, 2017   Mostyn Law and Gulf ... Houston, Texas . The Mostyn Law family ... 2 years. That is why Mostyn Law is partnering ... to show its appreciation. Blood supplies are running ... 5% short of hospital needs in August. That is why the ...
(Date:8/15/2017)... AccuGenomics, Inc., a diagnostic company based in ... the company has provided an AccuKit to the HIV ... Chapel Hill and to Qura Therapeutics for evaluation in ... HIV reservoir and viral expression in human CD4+ T ... Center is a joint initiative between the University of ...
Breaking Medicine Technology:
(Date:8/21/2017)... , ... August 21, 2017 , ... The experts have ... are we supposed to get things done in a healthy way these days? FlexiSpot, ... launching a crowdfunding campaign on August 28 to introduce Deskcise Pro™– the world’s first ...
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and ... care reform plan, has announced his candidacy for the 52nd Congressional District currently held ... in America’s Promise. Coming to this country at age eleven after suffering homelessness and ...
(Date:8/20/2017)... (PRWEB) , ... August 20, 2017 , ... A total solar eclipse will ... a few minutes as the moon moves between the sun and Earth. This rare event ... These four tips can help keep you safe on the road during the total eclipse ...
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with gluten intolerance or ... may be interested in participating in a research study that focuses on family interactions ... more about the relational aspects of adults who have gluten sensitivities who cohabitate with ...
(Date:8/19/2017)... , ... August 18, 2017 , ... ... aimed at creating a transparent, verifiable database to help the cannabis industry move ... technology, Paragon hopes to deliver a faster technology with lower fees. Paragon will ...
Breaking Medicine News(10 mins):